INV-102
Asset
Activates innate mucosal immune repair pathways and promotes corneal/retinal epithelial healing.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 5
- Indications
- 1
- Trial
- 1
- Developer
Indications
5Center-involved diabetic macular edema
Phase 2, Completed, NCT06599684, clinicaltrials.gov, 7 Oct 2026
Center-involved diabetic macular edema associated with non-proliferative diabetic retinopathy
Phase 2, Completed, NCT06599684, clinicaltrials.gov, 7 Oct 2026
Diabetic retinopathy
Phase 2, Completed, NCT06599684, clinicaltrials.gov, 7 Oct 2026
2 more
In the full profile
- Owner and partners1
- Trials1
- Competitors3
Every asset’s record: target, stage, trials and the evidence behind it.